Travere Therapeutics Current Valuation vs. Price To Book

TVTX Stock  USD 19.37  0.01  0.05%   
Based on Travere Therapeutics' profitability indicators, Travere Therapeutics may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in January. Profitability indicators assess Travere Therapeutics' ability to earn profits and add value for shareholders. At this time, Travere Therapeutics' Price To Sales Ratio is fairly stable compared to the past year. Days Sales Outstanding is likely to rise to 84.59 in 2024, whereas Sales General And Administrative To Revenue is likely to drop 1.09 in 2024. At this time, Travere Therapeutics' Total Other Income Expense Net is fairly stable compared to the past year. Income Tax Expense is likely to rise to about 234.2 K in 2024, despite the fact that Accumulated Other Comprehensive Income is likely to grow to (1.4 M).
Current ValueLast YearChange From Last Year 10 Year Trend
Gross Profit Margin1.070.9212
Fairly Up
Very volatile
For Travere Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Travere Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Travere Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Travere Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Travere Therapeutics over time as well as its relative position and ranking within its peers.
  

Travere Therapeutics' Revenue Breakdown by Earning Segment

Check out World Market Map.
For more information on how to buy Travere Stock please use our How to Invest in Travere Therapeutics guide.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Travere Therapeutics. If investors know Travere will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Travere Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(4.52)
Revenue Per Share
2.634
Quarterly Revenue Growth
0.696
Return On Assets
(0.26)
Return On Equity
(2.80)
The market value of Travere Therapeutics is measured differently than its book value, which is the value of Travere that is recorded on the company's balance sheet. Investors also form their own opinion of Travere Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Travere Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Travere Therapeutics' market value can be influenced by many factors that don't directly affect Travere Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Travere Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Travere Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Travere Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Travere Therapeutics Price To Book vs. Current Valuation Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Travere Therapeutics's current stock value. Our valuation model uses many indicators to compare Travere Therapeutics value to that of its competitors to determine the firm's financial worth.
Travere Therapeutics is rated below average in current valuation category among its peers. It is currently regarded as top stock in price to book category among its peers . The ratio of Current Valuation to Price To Book for Travere Therapeutics is about  23,794,843 . Price To Book Ratio is likely to drop to 3.16 in 2024. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Travere Therapeutics' earnings, one of the primary drivers of an investment's value.

Travere Current Valuation vs. Competition

Travere Therapeutics is rated below average in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Health Care industry is at this time estimated at about 63.72 Billion. Travere Therapeutics holds roughly 1.81 Billion in current valuation claiming about 2.84% of equities under Health Care industry.

Travere Price To Book vs. Current Valuation

Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.

Travere Therapeutics

Enterprise Value

 = 

Market Cap + Debt

-

Cash

 = 
1.81 B
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.

Travere Therapeutics

P/B

 = 

MV Per Share

BV Per Share

 = 
76.10 X
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.

Travere Price To Book Comparison

Travere Therapeutics is currently under evaluation in price to book category among its peers.

Travere Therapeutics Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Travere Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Travere Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Travere Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Travere Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive Income-1.5 M-1.4 M
Operating Income-376.7 M-357.9 M
Income Before Tax-376.1 M-357.3 M
Total Other Income Expense Net634 K665.7 K
Net Loss-376.3 M-357.5 M
Income Tax Expense223 K234.2 K
Net Interest Income10.4 M11 M
Net Loss-376.3 M-357.5 M
Net Loss-250.6 M-238.1 M
Interest Income21.8 M22.9 M
Non Operating Income Net Other-295.2 K-280.4 K
Change To Netincome37.4 M43.7 M
Net Loss(1.50)(1.57)
Income Quality 0.74  0.78 
Net Income Per E B T 0.30  0.28 

Travere Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Travere Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Travere Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Travere Therapeutics' important profitability drivers and their relationship over time.

Use Travere Therapeutics in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Travere Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Travere Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Travere Therapeutics Pair Trading

Travere Therapeutics Pair Trading Analysis

The ability to find closely correlated positions to Travere Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Travere Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Travere Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Travere Therapeutics to buy it.
The correlation of Travere Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Travere Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Travere Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Travere Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Travere Therapeutics position

In addition to having Travere Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Sector ETFs Thematic Idea Now

Sector ETFs
Sector ETFs Theme
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Sector ETFs theme has 439 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Sector ETFs Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for Travere Stock Analysis

When running Travere Therapeutics' price analysis, check to measure Travere Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Travere Therapeutics is operating at the current time. Most of Travere Therapeutics' value examination focuses on studying past and present price action to predict the probability of Travere Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Travere Therapeutics' price. Additionally, you may evaluate how the addition of Travere Therapeutics to your portfolios can decrease your overall portfolio volatility.